(Q81785770)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15916838%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

title

Effective nasal influenza vaccine delivery using chitosan (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15916838%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15916838%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

author name string

Simone C Naylor

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15916838%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

Christopher W Potter

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15916838%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

Jenny Bond

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15916838%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

Inderjit Jabbal-Gill

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15916838%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

Anthony Fisher

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15916838%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

Lisbeth Illum

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15916838%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

Roy Jennings

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15916838%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

publication date

1 August 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15916838%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

number of pages

8

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15916838%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

volume

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15916838%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

page(s)

4367-4374

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15916838%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

issue

35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15916838%20AND%20SRC:MED&resulttype=core&format=json

Reduction in mortality associated with influenza vaccine during 1989-90 epidemic.

12 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.021

Improvement of inactivated influenza virus vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.021

Intranasal immunization with inactivated influenza vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.021

The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.021

The aging immune system: primer and prospectus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.021

Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.021

Heterosubtypic immunity to lethal influenza A virus infection is associated with virus-specific CD8(+) cytotoxic T lymphocyte responses induced in mucosa-associated tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.021

Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.021

Immunity following intranasal administration of an inactivated, freeze-dried A/England/42/72 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.021

A nasal Proteosome influenza vaccine containing baculovirus-derived hemagglutinin induces protective mucosal and systemic immunity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.021

Protection against influenza virus infection by intranasal administration of C3d-fused hemagglutinin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.021

Development of immune response that protects mice from viral pneumonitis after a single intranasal immunization with influenza A virus and nanoemulsion.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.021

Stimulation of mucosal and systemic antibody responses against Bordetella pertussis filamentous haemagglutinin and recombinant pertussis toxin after nasal administration with chitosan in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.021

Chitosan as a novel nasal delivery system for vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.021

A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM(197)) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.021

The concomitant use of the LTK63 mucosal adjuvant and of chitosan-based delivery system enhances the immunogenicity and efficacy of intranasally administered vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.021

Modulation of immune response to group C meningococcal conjugate vaccine given intranasally to mice together with the LTK63 mucosal adjuvant and the trimethyl chitosan delivery system.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.021

Glycol chitosan improves the efficacy of intranasally administrated replication defective human adenovirus type 5 expressing glycoprotein D of bovine herpesvirus 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.021

Responses of volunteers to inactivated influenza virus vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.021

The efficacy of the A2/Aichi/68 strain in inhaled influenza immunisation against the A/England/42/72 variant.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.021

Developments in mucosal influenza virus vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.021

Adjuvants--a classification and review of their modes of action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.021

Immunopotentiation of local and systemic humoral immune responses by ISCOMs, liposomes and FCA: role in protection against influenza A in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.021

Enhancing effects of pertussis toxin B oligomer on the immunogenicity of influenza vaccine administered intranasally

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.021

Enhancement of immune response to intranasal influenza HA vaccine by microparticle resin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.021

Mutants of Escherichia coli heat-labile enterotoxin as an adjuvant for nasal influenza vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.021

Intranasal administration of a synthetic peptide vaccine encapsulated in liposome together with an anti-CD40 antibody induces protective immunity against influenza A virus in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.021

Pilot evaluation of influenza virus vaccine (IVV) combined with adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.021

Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.021

Mucosal antibody response induced with a nasal virosome-based influenza vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.021

Mucosal [SIgA] and serum [IgG] immunologic responses in the community after a single intra-nasal immunization with a new inactivated trivalent influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.021

Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosan.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.021

Nasal delivery of chitosan-DNA plasmid expressing epitopes of respiratory syncytial virus (RSV) induces protective CTL responses in BALB/c mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.04.021

10.1016/J.VACCINE.2005.04.021

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15916838%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

1 reference